SCHEMBL9985771

SCHEMBL9985771

CSc1ccc(SC)c(SC)c1[O]

nearest known ligand 0.32

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.32
PPARG P37231 1/20 0.32
NCOA2 Q15596 1/20 0.32
NCOA1 Q15788 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10745073 0.80 ALDH1A1 (0.32) ALDH1A1PPARGNCOA2NCOA1NPSR1
SCHEMBL9986066 0.78
SCHEMBL9986037 0.77 ALDH1A1 (0.31) ALDH1A1PPARGNCOA2NCOA1NPSR1
SCHEMBL9985363 0.77
SCHEMBL18378891 0.75 ALDH1A1 (0.34) ALDH1A1PPARGNCOA2NCOA1NPSR1
SCHEMBL199800 0.75 ALDH1A1 (0.39) ALDH1A1NPSR1SMN1; SMN2MEN1KMT2A
Ammonia Solution, Strong SCHEMBL16781733 0.72 ALDH1A1 (0.33) ALDH1A1PPARGNCOA2NCOA1NPSR1
SCHEMBL21830460 0.72
SCHEMBL6439887 0.70 GRM5 (0.36) ALDH1A1PPARGNCOA2NCOA1NPSR1
SCHEMBL9985773 0.68 MEN1 (0.34) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3130635-B1 RESIN COMPOSITION, CROSS-LINKED PRODUCT, AND METHOD FOR MANUFACTURING CROSS-LINKED PRODUCT SUMITOMO CHEMICAL CO (JP) 2020-02-26 EP disclosed
US-9909002-B2 Resin composition, cross-linked product, and method for manufacturing cross-linked product SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2018-03-06 US disclosed
US-9695260-B2 Method for producing olefin block polymer using plurality of types of transition metal catalysts SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-07-04 US disclosed
US-20170121516-A1 RESIN COMPOSITION, CROSS-LINKED PRODUCT, AND METHOD FOR MANUFACTURING CROSS-LINKED PRODUCT SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-05-04 US disclosed
US-9593194-B2 Method for producing olefin block polymer using group 4 transition metal complex SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-03-14 US disclosed
EP-3130635-A1 RESIN COMPOSITION, CROSS-LINKED PRODUCT, AND METHOD FOR MANUFACTURING CROSS-LINKED PRODUCT Sumitomo Chemical Company Limited (JP) 2017-02-15 EP disclosed
US-20140275429-A1 METHOD FOR PRODUCING OLEFIN BLOCK POLYMER USING PLURALITY OF TYPES OF TRANSITION METAL CATALYSTS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-09-18 US disclosed
US-20140163173-A1 METHOD FOR PRODUCING OLEFIN BLOCK POLYMER USING GROUP 4 TRANSITION METAL COMPLEX SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-06-12 US disclosed
US-8383848-B2 Transition metal compound and catalyst for olefin polymerization SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-02-26 US disclosed
US-20130041119-A1 OLEFIN POLYMER PRODUCING METHOD, ETHYLENE POLYMER, AND MOLD PRODUCT SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-02-14 US disclosed
US-20110319578-A1 TRANSITION METAL COMPOUND AND CATALYST FOR OLEFIN POLYMERIZATION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319578-A1 TRANSITION METAL COMPOUND AND CATALYST FOR OLEFIN POLYMERIZATION AP1M1, SOD1, YAP1 ALDH1A1 859/4885PPARG 4241/4885NCOA2 271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.